Format

Send to

Choose Destination
J Hypertens. 2015 Sep;33(9):1729-41; discussion 1741. doi: 10.1097/HJH.0000000000000701.

Serum uric acid and the risk of cardiovascular and renal disease.

Author information

1
aDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy bDepartment of Clinical and Experimental Sciences, University of Brescia, Department of Medicine, Spedali Civili, Brescia, Italy cAssistance Publique Hôpitaux de Paris, Hôpital Lariboisière dUniversité Paris Diderot, Sorbonne Paris Cité eINSERM, UMR 1132, Paris, France fInstitute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK gDepartment of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany hCardiology Department, Asklepeion Hospital, Athens, Greece iRheumatology Division, Hospital Universitario Cruces and Biocruces Health Research Institute, Vizcaya, Spain jUniversità Milano-Bicocca, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Abstract

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6  mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.

PMID:
26136207
DOI:
10.1097/HJH.0000000000000701
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center